Proteins Associated with Neurodevelopmental Disorders

This book comprehensively reviews the proteins associated with neurodevelopmental disorders, including autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). It also discusses the interactions of the associated-proteins, like bromodomain-containing proteins (BCPs), kinases, synaptic proteins, scaffolding proteins, transcriptional factors, and DNA-binding proteins at the subcellular and molecular levels. The book also explores the potential of these proteins as a druggable target and a biomarker in the neurodevelopmental disorders. The book further explores the recent advancements in understanding the important role of epigenetic factors in predisposition to these diseases. Lastly, it presents genetic factors that lead to variation in gene expression in these diseases, disorders management via diet intervention and the future potential of stem cell therapy.

Presents proteins that are associated with neurodevelopmental disorders Discusses the potential of these proteins as druggable targets Explores the genetic variations that modulate gene expression in these diseases

Auteur
Dr. M. Walid Qoronfleh, Ph.D., MBA, is currently the Executive Director of the US-based Q3CG Research Institute and a Senior Director at 21HealthStreet, London, UK. Prior, he was the Director of Healthcare Research and Policy at Qatar Foundation. Dr. Qoronfleh is engaged in project areas that are of immediate global and provincial healthcare relevance. His research interests are focused on neurodevelopmental disorders, mental health, patient safety, non-communicable diseases (cancer, diabetes & obesity), precision medicine and bioethics. Dr. Qoronfleh has over 20 years of scientific, technology, business, and commercial experience. He has held in the USA several senior management and executive positions with increasing responsibilities at GlaxoSmithKline, Sanofi, NIH-NCI, ThermoFisher, NextGen Sciences, SDIX and The University of Michigan-Ann Arbor, with a particular focus on precision medicine. Dr. Qoronfleh is the founder of three biotechnology companies and he is a co-founder andthe managing director of the boutique consulting company Q3CG. Dr. Qoronfleh has published over 100 peer-reviewed research articles in journals of high repute. He is also an editor and an ad hoc reviewer for various scientific journals and a frequent speaker at national and international conferences. He holds graduate degrees from The University of Louisville-School of Medicine, Penn State University and The University of Wisconsin-Madison.

Prof. Musthafa Mohamed Essa, Ph.D., is a Professor of Nutrition at Sultan Qaboos University, Oman. He is an Editor-in-Chief for the International Journal of Nutrition, Pharmacology, Neurological Diseases. He is also acting as an Associate Editor for BMC complementary and alternative medicine and is an Editor for Frontiers in Neuroscience and Frontiers in Biosciences. Prof. Essa is an expert in the field of Nutritional Neuroscience/ Neuropharmacology and has published more than 170 papers, 60 book chapters and 14 books. Prof. Essais the recipient of several awards, including the best book in the world, National Research Award, Outstanding neuroscientist, and Distinguished Researcher. He has over 15 years of research and teaching experience in the field of nutritional neuroscience and under his guidance 5 PhD and 10 master students completed their research. He is the Editor for a unique and first in kind book series titled "Nutritional Neurosciences" published by Springer Nature.

Prof. Saravana Babu Chidambaram, Ph.D., is a Professor in the Dept. of Pharmacology, JSS College of Pharmacy & Coordinator - Centre for Experimental Pharmacology & Toxicology, JSS Academy of Higher Education & Research University, Mysuru, India. He has 12 years of research and teaching experience in the field of Pharmacology and Toxicology. He has published more than 80 research articles in the field of neuropharmacology and toxicology. He is recipient of 'Outstanding Researcher in Pharmacology', VIRA (Sep, 2018), Dr. APJ Abdul Kalam Award for Scientific Excellence -2017, Marina Labs, Chennai (Sep, 2017). Recently he has established a GLP standard preclinical facility in JSS Academy of Higher Education & Research, Mysuru.

Contenu

Chapter 1 . Proteins Commonly Linked to Autism Spectrum Disorder.- Chapter 2 . Protein Aggregation and Recycling.- Chapter 3 . Neuron Membrane and Trafficking Protein Kinases (PKA&B) involved in ASD.- Chapter 4 . Proteomic profiling in children with ASD.- Chapter 5 . Molecular Protein biomarkers for developing diagnostics and therapeutic interventions.Gene Regulation in Autism. OR Neurodevelopmental Epigenomics.- Chapter 6 . Chromatin and Epigenetic Regulation in ASD.- Chapter 7 . Autism and the Scaffolding Protein Neurobeachin.- Chapter 8 . Genomic Profiling in ADHD subjects.- Chapter 9 . ADHD and Epigenetics Regulation.- Chapter 10 . Proteomic Approach in ADHD.- Chapter 11. DHD and the Dopamine Transporter (DAT).- Chapter 12 . Protein Kinases involved in ADHD.- Chapter 13 . ADHDand Cell Adhesion Molecule 1 CAM 1 (CADM1 gene).- Chapter 14 . ASD and Cell Adhesion Molecule Astrotactin.- Chapter 15 . Possible therapeutic interventions through proteins in ADHD.